Tanespimycin

Generic Name: Tanespimycin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₃₁H_₄₃N_₃O_₈

CAS Number: 75747-14-7

Unique Ingredient Identifier: 4GY0AVT3L4

Background: Tanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90). It is developed for the treatment of several types of cancer, solid tumors or chronic myelogenous leukemia.

Indication: Investigated for use/treatment in leukemia (myeloid) and solid tumors.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors

Phase 1

Completed

Conditions: Childhood Chronic Myelogenous Leukemia
Childhood Desmoplastic Small Round Cell Tumor
Disseminated Neuroblastoma
Metastatic Childhood Soft Tissue Sarcoma
Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Metastatic Osteosarcoma
Previously Treated Childhood Rhabdomyosarcoma
Recurrent Childhood Acute Lymphoblastic Leukemia
Recurrent Childhood Acute Myeloid Leukemia
Recurrent Childhood Rhabdomyosarcoma

Interventions: Drug: tanespimycin
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2004-10-08

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT00093821

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer

Phase 2

Completed

Conditions: Primary Peritoneal Cavity Cancer
Stage IV Ovarian Epithelial Cancer
Recurrent Ovarian Epithelial Cancer
Stage III Ovarian Epithelial Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: tanespimycin

First Posted Date: 2004-10-08

Last Posted Date: 2014-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 29

Registration Number: NCT00093496

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: tanespimycin
Drug: paclitaxel
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2004-07-12

Last Posted Date: 2013-01-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00087217

Locations: 🇺🇸
University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States

Tanespimycin in Treating Patients With Stage III-IV Melanoma

Phase 2

Terminated

Conditions: Recurrent Melanoma
Stage III Melanoma
Stage IV Melanoma

Interventions: Drug: tanespimycin
Other: laboratory biomarker analysis

First Posted Date: 2004-07-12

Last Posted Date: 2013-04-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT00087386

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Phase 1

Completed

Conditions: Acute Undifferentiated Leukemia
Recurrent Childhood Acute Lymphoblastic Leukemia
Recurrent Childhood Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia
Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Drug: tanespimycin

First Posted Date: 2004-03-10

Last Posted Date: 2013-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00079404

Locations: 🇺🇸
COG Phase I Consortium, Arcadia, California, United States

Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2003-08-07

Last Posted Date: 2013-04-05

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT00066326

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors

Phase 1

Completed

Conditions: Stage IV Prostate Cancer
Unspecified Adult Solid Tumor, Protocol Specific
Recurrent Prostate Cancer

Interventions: Drug: tanespimycin
Drug: docetaxel

First Posted Date: 2003-04-09

Last Posted Date: 2014-06-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 80

Registration Number: NCT00058253

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Phase 1

Terminated

Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Non-Hodgkin Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Grade 1 Follicular Lymphoma

Interventions: Drug: tanespimycin

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT00019708

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Geldanamycin Analogue in Treating Patients With Advanced Cancer

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-26

Lead Sponsor: Cancer Research UK

Registration Number: NCT00003969

Locations: 🇬🇧
Royal Marsden NHS Foundation Trust - London, London, England, United Kingdom

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

Phase 1

Completed

Conditions: Bladder Cancer
Breast Cancer
Colorectal Cancer
Gastric Cancer
Head and Neck Cancer
Kidney Cancer
Leukemia
Lung Cancer
Melanoma (Skin)
Ovarian Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00004065

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy